- Public Comps
- Biosynex
Biosynex Valuation Multiples
Discover Biosynex's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Trajan Group Holdings, EBM Technologies, European Medical Solutions, Resonance Health and more.
Biosynex Overview
About Biosynex
Biosynex SA is engaged in the research, development, and manufacturing of fast diagnosis tests on membrane support for health professionals. It manufactures and markets medical devices for screening, diagnosis.
Founded
2005
HQ

Employees
128
Website
Financials (LTM)
EV
$81M
Valuation Multiples
Start free trialBiosynex Financials
Biosynex reported last 12-month revenue of $110M and negative EBITDA of ($16M).
In the same LTM period, Biosynex generated ($16M) in EBITDA losses and had net loss of ($25M).
Biosynex P&L
In the most recent fiscal year, Biosynex reported revenue of $110M and EBITDA of ($2M).
Biosynex is unprofitable as of last fiscal year, with gross margin of 55%, EBITDA margin of (2%), and net margin of (61%).
Financial data powered by Morningstar, Inc.
Biosynex Stock Performance
Biosynex has current market cap of $19M, and enterprise value of $81M.
Market Cap Evolution
Biosynex's stock price is $1.02.
Biosynex share price decreased by 2.1% in the last 30 days, and increased by 26.1% in the last year.
Biosynex has an EPS (earnings per share) of $-3.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $81M | $19M | -1.5% | -2.1% | -0.8% | 26.1% | $-3.66 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiosynex Valuation Multiples
Biosynex trades at 0.7x EV/Revenue multiple, and (5.1x) EV/EBITDA.
Biosynex Financial Valuation Multiples
As of September 4, 2026, Biosynex has market cap of $19M and EV of $81M.
Biosynex has a P/E ratio of (0.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biosynex Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Biosynex Margins & Growth Rates
In the most recent fiscal year, Biosynex reported gross margin of 55%, EBITDA margin of (2%), and net margin of (61%).
Biosynex Margins
Biosynex Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Biosynex Operational KPIs
Biosynex's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $1.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Biosynex Competitors
Biosynex competitors include Trajan Group Holdings, EBM Technologies, European Medical Solutions, Resonance Health, Promimic, CelLBxHealth, Lifeward, SciBase Holding, Pulsenmore and SenzaGen.
Most Biosynex public comparables operate across Medical Devices, Medical Imaging & Diagnostics, HealthTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.4x | 0.4x | 7.3x | 5.2x | |||
| 2.0x | - | 18.9x | - | |||
| 0.6x | - | 6.3x | - | |||
| 2.4x | - | (29.4x) | - | |||
| 3.3x | - | (50.5x) | - | |||
| 8.5x | 6.2x | (0.7x) | (1.4x) | |||
| 0.8x | 0.7x | (0.9x) | - | |||
| 4.6x | 3.4x | (2.2x) | (2.0x) | |||
This data is available for Pro users. Sign up to see all Biosynex competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Biosynex
Biosynex has acquired 6 companies to date.
Last acquisition by Biosynex was on June 13th 2023. Biosynex acquired ProciseDx for undisclosed valuation.
Latest Acquisitions by Biosynex
| Description | ProciseDx is a diagnostics company specializing in point-of-care testing devices for rapid, accurate results. The platform delivers quantitative assays for biomarkers in minutes, enabling immediate clinical decisions without lab delays. Focused on infectious diseases and cardiac markers, ProciseDx devices integrate microfluidics and immunoassay technology. Based in Rockville, Maryland, it partners with healthcare providers to streamline patient workflows in clinics and emergency settings. | PARA’KITO is a Paris-headquartered company specializing in natural insect repellent technology. The firm manufactures wearable devices like bracelets and patches using a plant-based active ingredient effective against mosquitoes transmitting dengue, Zika, and malaria. PARA’KITO products are distributed in over 40 countries through pharmacies and retailers such as Boots and Walgreens, with clinical studies confirming up to eight hours of protection. | Avalun creates the Labpad, a portable in vitro diagnostic device yielding rapid test results from tiny sample volumes. | SR2B SA is a biotechnology firm developing reagents for microbiology and parasitology. Through http://www.sr2b.fr/, it produces parasitic antigens, fungal diagnostics, monoclonal antibodies, and lyophilized bioproducts with microparticle coupling for research labs in Europe. | |
| HQ Country | |||||
| HQ City | San Diego, CA | Fort Lauderdale, FL | Grenoble | Angers | |
| Deal Date | 13 Jun 2023 | 20 Apr 2022 | 3 May 2021 | 7 Jul 2017 | |
| Valuation | undisclosed | undisclosed | $12M | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Biosynex acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biosynex
| When was Biosynex founded? | Biosynex was founded in 2005. |
| Where is Biosynex headquartered? | Biosynex is headquartered in France. |
| How many employees does Biosynex have? | As of today, Biosynex has over 128 employees. |
| Is Biosynex publicly listed? | Yes, Biosynex is a public company listed on Euronext Paris. |
| What is the stock symbol of Biosynex? | Biosynex trades under ALBIO ticker. |
| When did Biosynex go public? | Biosynex went public in 2011. |
| Who are competitors of Biosynex? | Biosynex main competitors include Trajan Group Holdings, EBM Technologies, European Medical Solutions, Resonance Health, Promimic, CelLBxHealth, Lifeward, SciBase Holding, Pulsenmore, SenzaGen. |
| What is the current market cap of Biosynex? | Biosynex's current market cap is $19M. |
| What is the current revenue of Biosynex? | Biosynex's last 12 months revenue is $110M. |
| What is the current revenue growth of Biosynex? | Biosynex revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of Biosynex? | Current revenue multiple of Biosynex is 0.7x. |
| Is Biosynex profitable? | No, Biosynex is not profitable. |
| What is the current EBITDA of Biosynex? | Biosynex has negative EBITDA and is not profitable. |
| What is Biosynex's EBITDA margin? | Biosynex's last 12 months EBITDA margin is (14%). |
| What is the current EV/EBITDA multiple of Biosynex? | Current EBITDA multiple of Biosynex is (5.1x). |
| How many companies Biosynex has acquired to date? | As of September 2026, Biosynex has acquired 6 companies. |
| What was the largest acquisition by Biosynex? | $12M acquisition of Avalun on 3rd May 2021 was the largest M&A Biosynex has done to date. |
| What companies Biosynex acquired? | Biosynex acquired Avalun, Dectra Pharm, SR2B SA, ProciseDx, PARA’KITO, and Fumouze Diagnostics. |
| In how many companies Biosynex has invested to date? | Biosynex hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Biosynex
Lists including Biosynex
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.






